5-aminoimidazole-4-carboxamide ribonucleoside, (AICAr); 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase, (ATIC); 5-aminoimidazole-4-carboxamide ribonucleotide, (ZMP); 5-formamido-4-imidazolecarboxamide ribonucleotide, (FAICAR); AICA-ribosiduria; AMP-activated protein kinase, (AMPK); Alzheimer's disease; Development; Purine synthesis; RNA-seq; Tuberous Sclerosis Complex 1 and 2, (TSC1 and TSC2); adenine phosphoribosyltransferase, (APRT); adenosine monophosphate, (AMP); adenosine triphosphate, (ATP); adenylosuccinate lyase, (ADSL); arachidonic acid, (AA); cyclooxygenase, (COX); cytochrome, P450 (CYP); cytosolic phospholipase A2, (cPLA2); de novo purine synthesis, (DNPS); differentially expressed gene, (DEG); false discovery rate, (FDR); fatty acid amide hydrolase, (FAAH); fetal calf macroserum, (FCM); fetal calf serum, (FCS); fragments per kilobase of exon per million reads mapped, (FPKM); gene ontology, (GO); guanosine monophosphate, (GMP); inosine monophosphate, (IMP); interferon, (INF); lipoxygenase, (LOX); mammalian Target of Rapamycin, (mTOR); minus adenine crATIC to minus adenine WT comparison, (MM); phospholipase, (PLA); phosphoribosyl pyrophosphate, (PRPP); phosphoribosylaminoimidazole carboxylase/phosphoribosylaminoimidazole succinocarboxamide synthetase, (PAICS); plus adenine crATIC to plus adenine WT comparison, (PP); xanthine monophosphate, (XMP)